{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:29:54Z","timestamp":1793852994456,"version":"4.6.1"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["32003B_173193\/1"],"award-info":[{"award-number":["32003B_173193\/1"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Emerging evidence suggest migraine is a response to cerebral energy deficiency or oxidative stress in the brain. Beta-hydroxybutyrate (BHB) is likely able to circumvent some of the meta-bolic abnormalities reported in migraine. Exogenous BHB was given to test this assumption and, in this post-hoc analysis, multiple metabolic biomarkers were identified to predict \u00a0clinical improvements. A randomized clinical trial, involving 41 patients with episodic migraine. Each treatment period was 12 weeks long, followed by eight weeks of washout phase \/ second run-in phase before entering the corresponding second treatment period. The primary endpoint was the number of migraine days in the last 4 weeks of treatment adjusted for baseline. BHB re-sponders were identified (those with at least a 3-day reduction in migraine days over placebo) and its predictors were evaluated using Akaike\u2019s Information Criterion (AIC) stepwise boot-strapped analysis and logistic regression.  Responder analysis showed that metabolic markers could identify a \u201cmetabolic migraine\u201d subgroup, which responded to BHB with a 5.7 migraine days reduction compared to the placebo. This analysis provides further support for a \u201cmetabolic migraine\u201d subtype. Additionally, these analyses identified low-cost and easily accessible biomarkers that could guide recruitment in future research on this subgroup of patients.<\/jats:p><jats:p>This study is part of the trial registration: ClinicalTrials.gov: NCT03132233, registered on 27.04.2017, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03132233\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03132233<\/jats:ext-link><\/jats:p>","DOI":"10.1038\/s41598-023-28499-y","type":"journal-article","created":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T10:03:06Z","timestamp":1678183386000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Defining metabolic migraine with a distinct subgroup of patients with suboptimal inflammatory and metabolic markers"],"prefix":"10.1038","volume":"13","author":[{"given":"Elena C.","family":"Gross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niveditha","family":"Putananickal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Lena","family":"Orsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Schoenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Soto-Mota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,7]]},"reference":[{"key":"28499_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/ane.12229","volume":"129","author":"LJ Stovner","year":"2014","unstructured":"Stovner, L. J., Hoff, J. M., Svalheim, S. & Gilhus, N. E. Neurological disorders in the Global Burden of Disease 2010 study. Acta Neurol. Scand. 129, 1\u20136 (2014).","journal-title":"Acta Neurol. Scand."},{"key":"28499_CR2","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1210\/endo-19-5-549","volume":"19","author":"PA Gray","year":"1935","unstructured":"Gray, P. A. & Burtness, H. I. Hypoglycemic headache*. Endocrinology 19, 549\u2013560 (1935).","journal-title":"Endocrinology"},{"key":"28499_CR3","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/s41582-019-0255-4","volume":"15","author":"EC Gross","year":"2019","unstructured":"Gross, E. C., Lisicki, M., Fischer, D., S\u00e1ndor, P. S. & Schoenen, J. The metabolic face of migraine\u2014From pathophysiology to treatment. Nat. Rev. Neurol. 15, 627\u2013643 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"28499_CR4","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1212\/WNL.42.6.1209","volume":"42","author":"B Barbiroli","year":"1992","unstructured":"Barbiroli, B. et al. Abnormal brain and muscle energy metabolism shown by 31P magnetic resonance spectroscopy in patients affected by migraine with aura. Neurology 42, 1209\u20131214 (1992).","journal-title":"Neurology"},{"key":"28499_CR5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1468-2982.2009.01890.x","volume":"30","author":"JH Kim","year":"2010","unstructured":"Kim, J. H. et al. Interictal metabolic changes in episodic migraine: A voxel-based FDG-PET study. Cephalalgia 30, 53\u201361 (2010).","journal-title":"Cephalalgia"},{"key":"28499_CR6","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1203\/00006450-199712000-00024","volume":"42","author":"R Lodi","year":"1997","unstructured":"Lodi, R. et al. Deficit of brain and skeletal muscle bioenergetics and low brain magnesium in juvenile migraine: An in vivo31p magnetic resonance spectroscopy interictal study. Pediatr. Res. 42, 866\u2013871 (1997).","journal-title":"Pediatr. Res."},{"key":"28499_CR7","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S0361-9230(01)00440-3","volume":"54","author":"R Lodi","year":"2001","unstructured":"Lodi, R. et al. Deficient energy metabolism is associated with low free magnesium in the brains of patients with migraine and cluster headache. Brain Res. Bull. 54, 437\u2013441 (2001).","journal-title":"Brain Res. Bull."},{"key":"28499_CR8","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1212\/WNL.44.4.666","volume":"44","author":"P Montagna","year":"1994","unstructured":"Montagna, P. et al. 31P-magnetic resonance spectroscopy in migraine without aura. Neurology 44, 666\u2013669 (1994).","journal-title":"Neurology"},{"key":"28499_CR9","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1177\/0333102412452048","volume":"32","author":"H Reyngoudt","year":"2012","unstructured":"Reyngoudt, H., Achten, E. & Paemeleire, K. Magnetic resonance spectroscopy in migraine: What have we learned so far?. Cephalalgia 32, 845\u2013859 (2012).","journal-title":"Cephalalgia"},{"key":"28499_CR10","doi-asserted-by":"publisher","first-page":"3102","DOI":"10.1093\/brain\/awm165","volume":"130","author":"UG Schulz","year":"2007","unstructured":"Schulz, U. G. et al. Association between cortical metabolite levels and clinical manifestations of migrainous aura: An MR-spectroscopy study. Brain 130, 3102\u20133110 (2007).","journal-title":"Brain"},{"key":"28499_CR11","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1212\/WNL.39.4.538","volume":"39","author":"KM Welch","year":"1989","unstructured":"Welch, K. M., Levine, S. R., D\u2019Andrea, G., Schultz, L. R. & Helpern, J. A. Preliminary observations on brain energy metabolism in migraine studied by in vivo phosphorus 31 NMR spectroscopy. Neurology 39, 538\u2013541 (1989).","journal-title":"Neurology"},{"key":"28499_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0022-510X(96)00287-0","volume":"146","author":"R Lodi","year":"1997","unstructured":"Lodi, R. et al. Quantitative analysis of skeletal muscle bioenergetics and proton efflux in migraine and cluster headache. J. Neurol. Sci. 146, 73\u201380 (1997).","journal-title":"J. Neurol. Sci."},{"key":"28499_CR13","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1046\/j.1468-2982.1990.1005263.x","volume":"10","author":"B Barbiroli","year":"1990","unstructured":"Barbiroli, B. et al. Complicated migraine studied by phosphorus magnetic resonance spectroscopy. Cephalalgia 10, 263\u2013272 (1990).","journal-title":"Cephalalgia"},{"key":"28499_CR14","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1177\/0333102410394675","volume":"31","author":"H Reyngoudt","year":"2011","unstructured":"Reyngoudt, H., Paemeleire, K., Descamps, B., De Deene, Y. & Achten, E. 31P-MRS demonstrates a reduction in high-energy phosphates in the occipital lobe of migraine without aura patients. Cephalalgia 31, 1243\u20131253 (2011).","journal-title":"Cephalalgia"},{"key":"28499_CR15","doi-asserted-by":"publisher","first-page":"4543","DOI":"10.1038\/s41598-021-84102-2","volume":"11","author":"EC Gross","year":"2021","unstructured":"Gross, E. C. et al. Mitochondrial function and oxidative stress markers in higher-frequency episodic migraine. Sci. Rep. 11, 4543 (2021).","journal-title":"Sci. Rep."},{"key":"28499_CR16","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S0140-6736(71)91662-X","volume":"297","author":"JM Hockaday","year":"1971","unstructured":"Hockaday, J. M., Williamson, D. H. & Whitty, C. W. M. Blood-glucose levels and fatty-acid metabolism in migraine related to fasting. Lancet 297, 1153\u20131156 (1971).","journal-title":"Lancet"},{"key":"28499_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/0022-510X(77)90181-2","volume":"33","author":"SW Shaw","year":"1977","unstructured":"Shaw, S. W., Johnson, R. H. & Keogh, H. J. Metabolic changes during glucose tolerance tests in migraine attacks. J. Neurol. Sci. 33, 51\u201359 (1977).","journal-title":"J. Neurol. Sci."},{"key":"28499_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1111\/j.1526-4610.1978.hed1802091.x","volume":"18","author":"JD Dexter","year":"1978","unstructured":"Dexter, J. D., Roberts, J. & Byer, J. A. The five hour glucose tolerance test and effect of low sucrose diet in migraine. Headache 18, 91\u201394 (1978).","journal-title":"Headache"},{"key":"28499_CR19","doi-asserted-by":"publisher","first-page":"240","DOI":"10.11607\/ofph.1843","volume":"31","author":"X Wang","year":"2017","unstructured":"Wang, X. et al. Are glucose and insulin metabolism and diabetes associated with migraine? A community-based, case-control study. J. Oral Facial Pain Headache 31, 240\u2013250 (2017).","journal-title":"J. Oral Facial Pain Headache"},{"key":"28499_CR20","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/j.1468-2982.2005.00928.x","volume":"25","author":"I Rainero","year":"2005","unstructured":"Rainero, I. et al. Insulin sensitivity is impaired in patients with migraine. Cephalalgia 25, 593\u2013597 (2005).","journal-title":"Cephalalgia"},{"key":"28499_CR21","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/ene.12289","volume":"21","author":"A Fava","year":"2014","unstructured":"Fava, A. et al. Chronic migraine in women is associated with insulin resistance: A cross-sectional study. Eur. J. Neurol. 21, 267\u2013272 (2014).","journal-title":"Eur. J. Neurol."},{"key":"28499_CR22","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1111\/j.1526-4610.2007.00719.x","volume":"47","author":"C Cavestro","year":"2007","unstructured":"Cavestro, C. et al. Insulin metabolism is altered in migraineurs: A new pathogenic mechanism for migraine?. Headache 47, 1436\u20131442 (2007).","journal-title":"Headache"},{"key":"28499_CR23","doi-asserted-by":"publisher","first-page":"469529","DOI":"10.1155\/2015\/469529","volume":"2015","author":"MM Shaik","year":"2015","unstructured":"Shaik, M. M. & Gan, S. H. Vitamin supplementation as possible prophylactic treatment against migraine with aura and menstrual migraine. Biomed. Res. Int. 2015, 469529 (2015).","journal-title":"Biomed. Res. Int."},{"key":"28499_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.eujim.2017.10.003","volume":"16","author":"M Dahri","year":"2017","unstructured":"Dahri, M., Hashemilar, M., Asghari-Jafarabadi, M. & Tarighat-Esfanjani, A. Efficacy of coenzyme Q10 for the prevention of migraine in women: A randomized, double-blind, placebo-controlled study. Eur. J. Integr. Med. 16, 8\u201314 (2017).","journal-title":"Eur. J. Integr. Med."},{"key":"28499_CR25","first-page":"1","volume":"0","author":"M Dahri","year":"2018","unstructured":"Dahri, M., Tarighat-Esfanjani, A., Asghari-Jafarabadi, M. & Hashemilar, M. Oral coenzyme Q10 supplementation in patients with migraine: Effects on clinical features and inflammatory markers. Nutr. Neurosci. 0, 1\u20139 (2018).","journal-title":"Nutr. Neurosci."},{"key":"28499_CR26","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1212\/01.WNL.0000151975.03598.ED","volume":"64","author":"PS S\u00e1ndor","year":"2005","unstructured":"S\u00e1ndor, P. S. et al. Efficacy of coenzyme Q10 in migraine prophylaxis: A randomized controlled trial. Neurology 64, 713\u2013715 (2005).","journal-title":"Neurology"},{"key":"28499_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418821661","author":"P Hajihashemi","year":"2019","unstructured":"Hajihashemi, P., Askari, G., Khorvash, F., Reza Maracy, M. & Nourian, M. The effects of concurrent Coenzyme Q10, L-carnitine supplementation in migraine prophylaxis: A randomized, placebo-controlled, double-blind trial. Cephalalgia https:\/\/doi.org\/10.1177\/0333102418821661 (2019).","journal-title":"Cephalalgia"},{"key":"28499_CR28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s13760-016-0697-z","volume":"117","author":"A Shoeibi","year":"2017","unstructured":"Shoeibi, A. et al. Effectiveness of coenzyme Q10 in prophylactic treatment of migraine headache: An open-label, add-on, controlled trial. Acta Neurol. Belg. 117, 103\u2013109 (2017).","journal-title":"Acta Neurol. Belg."},{"key":"28499_CR29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1046\/j.1468-2982.2002.00335.x","volume":"22","author":"T Rozen","year":"2002","unstructured":"Rozen, T. et al. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 22, 137\u2013141 (2002).","journal-title":"Cephalalgia"},{"key":"28499_CR30","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1468-1331.2004.00813.x","volume":"11","author":"C Boehnke","year":"2004","unstructured":"Boehnke, C. et al. High-dose riboflavin treatment is efficacious in migraine prophylaxis: An open study in a tertiary care centre. Eur. J. Neurol. 11, 475\u2013477 (2004).","journal-title":"Eur. J. Neurol."},{"key":"28499_CR31","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s10194-009-0142-2","volume":"10","author":"M Cond\u00f2","year":"2009","unstructured":"Cond\u00f2, M., Posar, A., Arbizzani, A. & Parmeggiani, A. Riboflavin prophylaxis in pediatric and adolescent migraine. J Headache Pain 10, 361\u2013365 (2009).","journal-title":"J Headache Pain"},{"key":"28499_CR32","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1186\/s10194-015-0516-6","volume":"16","author":"C Gaul","year":"2015","unstructured":"Gaul, C., Diener, H.-C., Danesch, U., Migravent\u00ae Study Group, on behalf of the M. S. Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: A randomized, placebo-controlled, double-blind, multicenter trial. J. Headache Pain 16, 516 (2015).","journal-title":"J. Headache Pain"},{"key":"28499_CR33","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1212\/WNL.50.2.466","volume":"50","author":"J Schoenen","year":"1998","unstructured":"Schoenen, J., Jacquy, J. & Lenaerts, M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 50, 466\u2013470 (1998).","journal-title":"Neurology"},{"key":"28499_CR34","first-page":"171","volume":"39","author":"A Rahimdel","year":"2014","unstructured":"Rahimdel, A., Mellat, A., Zeinali, A., Jafari, E. & Ayatollahi, P. Comparison between intravenous sodium valproate and subcutaneous sumatriptan for treatment of acute migraine attacks; double-blind randomized clinical trial. Iran J. Med. Sci. 39, 171\u2013177 (2014).","journal-title":"Iran J. Med. Sci."},{"key":"28499_CR35","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/jcpt.12548","volume":"42","author":"DF Thompson","year":"2017","unstructured":"Thompson, D. F. & Saluja, H. S. Prophylaxis of migraine headaches with riboflavin: A systematic review. J. Clin. Pharm. Ther. 42, 394\u2013403 (2017).","journal-title":"J. Clin. Pharm. Ther."},{"key":"28499_CR36","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1212\/WNL.0b013e3181a41269","volume":"72","author":"C Di Lorenzo","year":"2009","unstructured":"Di Lorenzo, C. et al. Mitochondrial DNA haplogroups influence the therapeutic response to riboflavin in migraineurs. Neurology 72, 1588\u20131594 (2009).","journal-title":"Neurology"},{"key":"28499_CR37","first-page":"E97","volume":"19","author":"H-Y Chiu","year":"2016","unstructured":"Chiu, H.-Y., Yeh, T.-H., Huang, Y.-C. & Chen, P.-Y. Effects of intravenous and oral magnesium on reducing migraine: A meta-analysis of randomized controlled trials. Pain Physician 19, E97-112 (2016).","journal-title":"Pain Physician"},{"key":"28499_CR38","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1111\/j.1526-4610.2006.00626.x","volume":"47","author":"D Magis","year":"2007","unstructured":"Magis, D. et al. A randomized double-blind placebo-controlled trial of thioctic acid in migraine prophylaxis. Headache 47, 52\u201357 (2007).","journal-title":"Headache"},{"key":"28499_CR39","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1089\/jmf.2017.0068","volume":"21","author":"C Cavestro","year":"2018","unstructured":"Cavestro, C. et al. Alpha-lipoic acid shows promise to improve migraine in patients with insulin resistance: A 6-month exploratory study. J. Med. Food 21, 269\u2013273 (2018).","journal-title":"J. Med. Food"},{"key":"28499_CR40","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jsps.2010.07.006","volume":"18","author":"AM Ali","year":"2010","unstructured":"Ali, A. M., Awad, T. G. & Al-Adl, N. M. Efficacy of combined topiramate\/thioctic acid therapy in migraine prophylaxis. Saudi Pharm. J. 18, 239\u2013243 (2010).","journal-title":"Saudi Pharm. J."},{"key":"28499_CR41","doi-asserted-by":"publisher","DOI":"10.1111\/head.12725","author":"JM Borkum","year":"2015","unstructured":"Borkum, J. M. Migraine triggers and oxidative stress: A narrative review and synthesis. Headache https:\/\/doi.org\/10.1111\/head.12725 (2015).","journal-title":"Headache"},{"key":"28499_CR42","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1111\/bph.12512","volume":"171","author":"S Benemei","year":"2014","unstructured":"Benemei, S., Fusi, C., Trevisan, G. & Geppetti, P. The TRPA1 channel in migraine mechanism and treatment. Br. J. Pharmacol. 171, 2552\u20132567 (2014).","journal-title":"Br. J. Pharmacol."},{"key":"28499_CR43","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1089\/ars.2013.5616","volume":"21","author":"D Kozai","year":"2014","unstructured":"Kozai, D., Ogawa, N. & Mori, Y. Redox regulation of transient receptor potential channels. Antioxid. Redox Signal. 21, 971\u2013986 (2014).","journal-title":"Antioxid. Redox Signal."},{"key":"28499_CR44","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1111\/j.1526-4610.2006.00321_5.x","volume":"46","author":"RS Strahlman","year":"2006","unstructured":"Strahlman, R. S. Can ketosis help migraine sufferers? A case report. Headache 46, 182 (2006).","journal-title":"Headache"},{"key":"28499_CR45","first-page":"305","volume":"28","author":"C Di Lorenzo","year":"2013","unstructured":"Di Lorenzo, C. et al. Diet transiently improves migraine in two twin sisters: Possible role of ketogenesis?. Funct. Neurol. 28, 305\u2013308 (2013).","journal-title":"Funct. Neurol."},{"key":"28499_CR46","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1177\/0333102411412089","volume":"31","author":"F Maggioni","year":"2011","unstructured":"Maggioni, F., Margoni, M. & Zanchin, G. Ketogenic diet in migraine treatment: A brief but ancient history. Cephalalgia 31, 1150\u20131151 (2011).","journal-title":"Cephalalgia"},{"key":"28499_CR47","doi-asserted-by":"publisher","first-page":"341","DOI":"10.7326\/0003-4819-2-4-341","volume":"2","author":"TG Schnabel","year":"1928","unstructured":"Schnabel, T. G. An experience with a ketogenic dietary in migraine. Ann. Intern. Med. 2, 341 (1928).","journal-title":"Ann. Intern. Med."},{"key":"28499_CR48","doi-asserted-by":"publisher","DOI":"10.1111\/ene.12550","author":"C Di Lorenzo","year":"2014","unstructured":"Di Lorenzo, C. et al. Migraine improvement during short lasting ketogenesis: A proof-of-concept study. Eur. J. Neurol. https:\/\/doi.org\/10.1111\/ene.12550 (2014).","journal-title":"Eur. J. Neurol."},{"key":"28499_CR49","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s10194-016-0650-9","volume":"17","author":"C Di Lorenzo","year":"2016","unstructured":"Di Lorenzo, C. et al. Cortical functional correlates of responsiveness to short-lasting preventive intervention with ketogenic diet in migraine: A multimodal evoked potentials study. J. Headache Pain 17, 58 (2016).","journal-title":"J. Headache Pain"},{"key":"28499_CR50","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.yebeh.2004.10.006","volume":"6","author":"EE Bailey","year":"2005","unstructured":"Bailey, E. E., Pfeifer, H. H. & Thiele, E. A. The use of diet in the treatment of epilepsy. Epilepsy Behav. 6, 4\u20138 (2005).","journal-title":"Epilepsy Behav."},{"key":"28499_CR51","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1177\/0883073813487598","volume":"28","author":"NN Danial","year":"2013","unstructured":"Danial, N. N., Hartman, A. L., Stafstrom, C. E. & Thio, L. L. How does the ketogenic diet work? Four potential mechanisms. J. Child Neurol. 28, 1027\u20131033 (2013).","journal-title":"J. Child Neurol."},{"key":"28499_CR52","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3389\/fphar.2012.00059","volume":"3","author":"CE Stafstrom","year":"2012","unstructured":"Stafstrom, C. E. & Rho, J. M. The ketogenic diet as a treatment paradigm for diverse neurological disorders. Front. Pharmacol. 3, 59 (2012).","journal-title":"Front. Pharmacol."},{"key":"28499_CR53","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s11940-008-0043-8","volume":"10","author":"KW Bara\u00f1ano","year":"2008","unstructured":"Bara\u00f1ano, K. W. & Hartman, A. L. The ketogenic diet: Uses in epilepsy and other neurologic illnesses. Curr. Treat. Options. Neurol. 10, 410\u2013419 (2008).","journal-title":"Curr. Treat. Options. Neurol."},{"key":"28499_CR54","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/jnr.490180407","volume":"18","author":"J Edmond","year":"1987","unstructured":"Edmond, J., Robbins, R. A., Bergstrom, J. D., Cole, R. A. & de Vellis, J. Capacity for substrate utilization in oxidative metabolism by neurons, astrocytes, and oligodendrocytes from developing brain in primary culture. J. Neurosci. Res. 18, 551\u2013561 (1987).","journal-title":"J. Neurosci. Res."},{"key":"28499_CR55","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3389\/fphys.2014.00260","volume":"5","author":"EN Dedkova","year":"2014","unstructured":"Dedkova, E. N. & Blatter, L. A. Role of \u03b2-hydroxybutyrate, its polymer poly-\u03b2-hydroxybutyrate and inorganic polyphosphate in mammalian health and disease. Front. Physiol. 5, 260 (2014).","journal-title":"Front. Physiol."},{"key":"28499_CR56","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.cmet.2016.12.022","volume":"25","author":"P Puchalska","year":"2017","unstructured":"Puchalska, P. & Crawford, P. A. Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics. Cell Metab. 25, 262\u2013284 (2017).","journal-title":"Cell Metab."},{"key":"28499_CR57","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3390\/nu11040811","volume":"11","author":"EC Gross","year":"2019","unstructured":"Gross, E. C., Klement, R. J., Schoenen, J., D\u2019Agostino, D. P. & Fischer, D. Potential protective mechanisms of ketone bodies in migraine prevention. Nutrients 11, 811 (2019).","journal-title":"Nutrients"},{"key":"28499_CR58","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.seizure.2014.02.015","volume":"23","author":"M Nei","year":"2014","unstructured":"Nei, M., Ngo, L., Sirven, J. I. & Sperling, M. R. Ketogenic diet in adolescents and adults with epilepsy. Seizure 23, 439\u2013442 (2014).","journal-title":"Seizure"},{"key":"28499_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2014.06.001","author":"CA Reid","year":"2014","unstructured":"Reid, C. A., Mullen, S., Kim, T. H. & Petrou, S. Epilepsy, energy deficiency and new therapeutic approaches including diet. Pharmacol. Ther. https:\/\/doi.org\/10.1016\/j.pharmthera.2014.06.001 (2014).","journal-title":"Pharmacol. Ther."},{"key":"28499_CR60","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.neulet.2008.01.032","volume":"434","author":"M de Almeida Rabello Oliveira","year":"2008","unstructured":"de Almeida Rabello Oliveira, M. et al. Effects of short-term and long-term treatment with medium- and long-chain triglycerides ketogenic diet on cortical spreading depression in young rats. Neurosci. Lett. 434, 66\u201370 (2008).","journal-title":"Neurosci. Lett."},{"key":"28499_CR61","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1743-7075-6-31","volume":"6","author":"ST Henderson","year":"2009","unstructured":"Henderson, S. T. et al. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer\u2019s disease: A randomized, double-blind, placebo-controlled, multicenter trial. Nutr. Metab. 6, 31 (2009).","journal-title":"Nutr. Metab."},{"key":"28499_CR62","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1055\/s-2004-44906","volume":"216","author":"J Klepper","year":"2003","unstructured":"Klepper, J., Leiendecker, B., Riemann, E. & Baumeister, F. A. The ketogenic diet in German-speaking countries: Update. Klin. Padiatr. 216, 277\u2013285 (2003).","journal-title":"Klin. Padiatr."},{"key":"28499_CR63","doi-asserted-by":"publisher","first-page":"474296","DOI":"10.1155\/2014\/474296","volume":"2014","author":"A Paoli","year":"2014","unstructured":"Paoli, A., Bianco, A., Damiani, E. & Bosco, G. Ketogenic diet in neuromuscular and neurodegenerative diseases. Biomed. Res. Int. 2014, 474296 (2014).","journal-title":"Biomed. Res. Int."},{"key":"28499_CR64","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.yapd.2010.08.003","volume":"57","author":"JM Freeman","year":"2010","unstructured":"Freeman, J. M. & Kossoff, E. H. Ketosis and the ketogenic diet, 2010: Advances in treating epilepsy and other disorders. Adv. Pediatr. 57, 315\u2013329 (2010).","journal-title":"Adv. Pediatr."},{"key":"28499_CR65","doi-asserted-by":"publisher","first-page":"9","DOI":"10.4103\/2319-4170.107154","volume":"36","author":"YC Liu","year":"2013","unstructured":"Liu, Y. C. & Wang, H.-S. Medium-chain triglyceride ketogenic diet, an effective treatment for drug-resistant epilepsy and a comparison with other ketogenic diets. Biomed. J. 36, 9\u201315 (2013).","journal-title":"Biomed. J."},{"key":"28499_CR66","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1203\/PDR.0b013e318232154f","volume":"70","author":"V Valayannopoulos","year":"2011","unstructured":"Valayannopoulos, V. et al. Successful treatment of severe cardiomyopathy in glycogen storage disease type III with D, L-3-hydroxybutyrate, ketogenic and high-protein diet. Pediatr. Res. 70, 638\u2013641 (2011).","journal-title":"Pediatr. Res."},{"key":"28499_CR67","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.yrtph.2012.04.008","volume":"63","author":"K Clarke","year":"2012","unstructured":"Clarke, K. et al. Kinetics, safety and tolerability of (R)-3-hydroxybutyl (R)-3-hydroxybutyrate in healthy adult subjects. Regul. Toxicol. Pharmacol. 63, 401\u2013408 (2012).","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"28499_CR68","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.yebeh.2013.09.032","volume":"29","author":"EH Kossoff","year":"2013","unstructured":"Kossoff, E. H., Cervenka, M. C., Henry, B. J., Haney, C. A. & Turner, Z. A decade of the modified Atkins diet (2003\u20132013): Results, insights, and future directions. Epilepsy Behav. 29, 437\u2013442 (2013).","journal-title":"Epilepsy Behav."},{"key":"28499_CR69","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jalz.2014.01.006","volume":"11","author":"MT Newport","year":"2015","unstructured":"Newport, M. T., VanItallie, T. B., Kashiwaya, Y., King, M. T. & Veech, R. L. A new way to produce hyperketonemia: Use of ketone ester in a case of Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 11, 99\u2013103 (2015).","journal-title":"Alzheimer\u2019s Dement."},{"key":"28499_CR70","first-page":"2056","volume":"1852","author":"N Douris","year":"2015","unstructured":"Douris, N. et al. Adaptive changes in amino acid metabolism permit normal longevity in mice consuming a low-carbohydrate ketogenic diet. Biochem. Biophys. Acta 1852, 2056\u20132065 (2015).","journal-title":"Biochem. Biophys. Acta"},{"key":"28499_CR71","doi-asserted-by":"publisher","DOI":"10.1177\/03331024211043792","author":"N Putananickal","year":"2021","unstructured":"Putananickal, N. et al. Efficacy and safety of exogenous beta-hydroxybutyrate for preventive treatment in episodic migraine: A single-centred, randomised, placebo-controlled, double-blind crossover trial. Cephalalgia https:\/\/doi.org\/10.1177\/03331024211043792 (2021).","journal-title":"Cephalalgia"},{"key":"28499_CR72","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13063-018-3120-7","volume":"20","author":"E Gross","year":"2019","unstructured":"Gross, E. et al. Efficacy and safety of exogenous ketone bodies for preventive treatment of migraine: A study protocol for a single-centred, randomised, placebo-controlled, double-blind crossover trial. Trials 20, 61 (2019).","journal-title":"Trials"},{"key":"28499_CR73","doi-asserted-by":"crossref","unstructured":"The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia\u202f: an international journal of headache 33, 629\u2013808 (2013).","DOI":"10.1177\/0333102413485658"},{"key":"28499_CR74","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12955-018-0871-5","volume":"16","author":"T Benz","year":"2018","unstructured":"Benz, T. et al. Translation, cross-cultural adaptation and reliability of the German version of the migraine disability assessment (MIDAS) questionnaire. Health Qual. Life Outcomes 16, 42 (2018).","journal-title":"Health Qual. Life Outcomes"},{"key":"28499_CR75","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.jclinepi.2004.05.004","volume":"57","author":"M Martin","year":"2004","unstructured":"Martin, M., Blaisdell, B., Kwong, J. W. & Bjorner, J. B. The short-form headache impact test (HIT-6) was psychometrically equivalent in nine languages. J. Clin. Epidemiol. 57, 1271\u20131278 (2004).","journal-title":"J. Clin. Epidemiol."},{"key":"28499_CR76","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s10072-018-3547-3","volume":"39","author":"Y Zhu","year":"2018","unstructured":"Zhu, Y. et al. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: A meta-analysis. Neurol. Sci. 39, 2097\u20132106 (2018).","journal-title":"Neurol. Sci."},{"key":"28499_CR77","doi-asserted-by":"publisher","first-page":"848","DOI":"10.3389\/fphys.2017.00848","volume":"8","author":"BJ Stubbs","year":"2017","unstructured":"Stubbs, B. J. et al. On the metabolism of exogenous ketones in humans. Front. Physiol. 8, 848 (2017).","journal-title":"Front. Physiol."},{"key":"28499_CR78","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/(SICI)1520-7560(199911\/12)15:6<412::AID-DMRR72>3.0.CO;2-8","volume":"15","author":"L Laffel","year":"1999","unstructured":"Laffel, L. Ketone bodies: A review of physiology, pathophysiology and application of monitoring to diabetes. Diabetes Metab. Res. Rev. 15, 412\u2013426 (1999).","journal-title":"Diabetes Metab. Res. Rev."},{"key":"28499_CR79","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1038\/jcbfm.2013.87","volume":"33","author":"Y Zhang","year":"2013","unstructured":"Zhang, Y. et al. Ketosis proportionately spares glucose utilization in brain. J. Cereb. Blood Flow Metabol. 33, 1307\u20131311 (2013).","journal-title":"J. Cereb. Blood Flow Metabol."},{"key":"28499_CR80","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001049.pub2","author":"A Wakai","year":"2005","unstructured":"Wakai, A., Roberts, I. G., Schierhout, G. & Wakai, A. Mannitol for acute traumatic brain injury. Cochrane Database Syst. Rev. https:\/\/doi.org\/10.1002\/14651858.CD001049.pub2 (2005).","journal-title":"Cochrane Database Syst. Rev."},{"key":"28499_CR81","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1097\/CCM.0000000000001137","volume":"43","author":"C Schilte","year":"2015","unstructured":"Schilte, C. et al. Mannitol improves brain tissue oxygenation in a model of diffuse traumatic brain injury*. Crit. Care Med. 43, 2212\u20132218 (2015).","journal-title":"Crit. Care Med."},{"key":"28499_CR82","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/thx.2005.041996","volume":"61","author":"R Broekhuizen","year":"2006","unstructured":"Broekhuizen, R., Wouters, E. F. M., Creutzberg, E. C. & Schols, A. M. W. J. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 61, 17\u201322 (2006).","journal-title":"Thorax"},{"key":"28499_CR83","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/nyas.12374","volume":"1311","author":"EA McAninch","year":"2014","unstructured":"McAninch, E. A. & Bianco, A. C. Thyroid hormone signaling in energy homeostasis and energy metabolism. Ann. N. Y. Acad. Sci. 1311, 77\u201387 (2014).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"28499_CR84","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.2337\/diabetes.54.11.3140","volume":"54","author":"AJG Hanley","year":"2005","unstructured":"Hanley, A. J. G. et al. Liver markers and development of the metabolic syndrome: The insulin resistance atherosclerosis study. Diabetes 54, 3140\u20133147 (2005).","journal-title":"Diabetes"},{"key":"28499_CR85","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/bs.irn.2020.02.003","volume":"155","author":"NG Norwitz","year":"2020","unstructured":"Norwitz, N. G., Jaramillo, J. G., Clarke, K. & Soto, A. Ketotherapeutics for neurodegenerative diseases. Int. Rev. Neurobiol. 155, 141\u2013168. https:\/\/doi.org\/10.1016\/bs.irn.2020.02.003 (2020).","journal-title":"Int. Rev. Neurobiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28499-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28499-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28499-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T11:14:15Z","timestamp":1678187655000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28499-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,7]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["28499"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-28499-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,7]]},"assertion":[{"value":"16 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ECG and DF are the inventors of the patent WO 2018\/115158 Al held by the UKBB and University of Basel on the use of beta-hydroxybutyrate in migraine prevention. ECG is the founder of KetoSwiss AG. Other authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3787"}}